Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C4H2O6.2K.2Sb.3H2O |
| Molecular Weight | 667.873 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[K+].[K+].[Sb+3].[Sb+3].[O-][C@H]([C@@H]([O-])C([O-])=O)C([O-])=O.[O-][C@H]([C@@H]([O-])C([O-])=O)C([O-])=O
InChI
InChIKey=WBTCZEPSIIFINA-MSFWTACDSA-J
InChI=1S/2C4H4O6.2K.3H2O.2Sb/c2*5-1(3(7)8)2(6)4(9)10;;;;;;;/h2*1-2H,(H,7,8)(H,9,10);;;3*1H2;;/q2*-2;2*+1;;;;2*+3/p-4/t2*1-,2-;;;;;;;/m11......./s1
DescriptionSources: https://www.whocc.no/atcvet/atcvet_index/?code=QR05CA07https://www.ncbi.nlm.nih.gov/pubmed/5295139 | https://www.ncbi.nlm.nih.gov/pubmed/14851220 | https://www.ncbi.nlm.nih.gov/pubmed/8898332Curator's Comment: description was created based on several sources, including https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ef48d40-6d63-440b-a73c-46d89f425936
Sources: https://www.whocc.no/atcvet/atcvet_index/?code=QR05CA07https://www.ncbi.nlm.nih.gov/pubmed/5295139 | https://www.ncbi.nlm.nih.gov/pubmed/14851220 | https://www.ncbi.nlm.nih.gov/pubmed/8898332
Curator's Comment: description was created based on several sources, including https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ef48d40-6d63-440b-a73c-46d89f425936
Stibophen (Fuadin), an organic trivalent antimony compound, has been used for many years in the treatment of schistosomiasis. Stibophen is used as treatment of schistosomiasis by intramuscular injection. Stibophen is known to act by selectively inhibiting worm PFK.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Investigation on the pharmacological profile of 2,6-diacetylpyridine bis(benzoylhydrazone) derivatives and their antimony(III) and bismuth(III) complexes. | 2012-07 |
|
| Antimony impairs nucleotide excision repair: XPA and XPE as potential molecular targets. | 2010-07-19 |
|
| Purification, kinetics and inhibition by antimonials of recombinant phosphofructokinase from Schistosoma mansoni. | 1996-10-30 |
|
| [Substantiation of maximum permissible levels of antimony trioxide and pentasulide in the atmospheric air of inhabitated places]. | 1989-04 |
|
| Current chemotherapy of schistosomiasis japonica in the Philippines. | 1976-06 |
|
| Laboratory studies on the joint effects of certain tris (p-aminophenyl) carbonium salts and antimonials as antischistosomal drugs. | 1965 |
|
| Evaluation of fuadin therapy in schistosomiasis japonica. | 1951-04 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C737
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
||
|
EPA PESTICIDE CODE |
6201
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ANTIMONY POTASSIUM TARTRATE
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
28300-74-5
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
DL6OZ476V3
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
m1961
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
C76863
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
1428
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
2761
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
981
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB34747
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
73415808
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
DB15587
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
SUB127075
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
ALTERNATIVE | |||
|
SUB12916MIG
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
300000056468
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
DL6OZ476V3
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY | |||
|
D000966
Created by
admin on Mon Mar 31 18:04:16 GMT 2025 , Edited by admin on Mon Mar 31 18:04:16 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD